Unknown

Dataset Information

0

Structural Bases of Noncompetitive Inhibition of AMPA-Subtype Ionotropic Glutamate Receptors by Antiepileptic Drugs.


ABSTRACT: Excitatory neurotransmission plays a key role in epileptogenesis. Correspondingly, AMPA-subtype ionotropic glutamate receptors, which mediate the majority of excitatory neurotransmission and contribute to seizure generation and spread, have emerged as promising targets for epilepsy therapy. The most potent and well-tolerated AMPA receptor inhibitors act via a noncompetitive mechanism, but many of them produce adverse side effects. The design of better drugs is hampered by the lack of a structural understanding of noncompetitive inhibition. Here, we report crystal structures of the rat AMPA-subtype GluA2 receptor in complex with three noncompetitive inhibitors. The inhibitors bind to a novel binding site, completely conserved between rat and human, at the interface between the ion channel and linkers connecting it to the ligand-binding domains. We propose that the inhibitors stabilize the AMPA receptor closed state by acting as wedges between the transmembrane segments, thereby preventing gating rearrangements that are necessary for ion channel opening.

SUBMITTER: Yelshanskaya MV 

PROVIDER: S-EPMC5033713 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structural Bases of Noncompetitive Inhibition of AMPA-Subtype Ionotropic Glutamate Receptors by Antiepileptic Drugs.

Yelshanskaya Maria V MV   Singh Appu K AK   Sampson Jared M JM   Narangoda Chamali C   Kurnikova Maria M   Sobolevsky Alexander I AI  

Neuron 20160908 6


Excitatory neurotransmission plays a key role in epileptogenesis. Correspondingly, AMPA-subtype ionotropic glutamate receptors, which mediate the majority of excitatory neurotransmission and contribute to seizure generation and spread, have emerged as promising targets for epilepsy therapy. The most potent and well-tolerated AMPA receptor inhibitors act via a noncompetitive mechanism, but many of them produce adverse side effects. The design of better drugs is hampered by the lack of a structura  ...[more]

Similar Datasets

| S-EPMC4703952 | biostudies-literature
| S-EPMC3458792 | biostudies-literature
| S-EPMC4879209 | biostudies-literature
| S-EPMC5743206 | biostudies-literature
| S-EPMC1783868 | biostudies-literature
| S-EPMC2972219 | biostudies-literature
| S-EPMC2709536 | biostudies-literature
| S-EPMC3050028 | biostudies-literature
| S-EPMC5780838 | biostudies-literature
| S-EPMC5082733 | biostudies-literature